Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Allergan Limited, Marlow International, The Parkway, Marlow, Buckinghamshire, SL7 1YL, United Kingdom
Betagan Unit Dose.
| Pharmaceutical Form |
|---|
|
Eye Drops, solution. A clear, colourless to brown solution. |
One ml solution contains 5.0 mg levobunolol hydrochloride, equivalent to 4.4 mg levobunolol.
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Levobunolol |
Levobunolol is a non-cardioselective beta-adrenoceptor blocking agent, equipotent at both beta1 and beta2 receptors. The primary mechanism of action of levobunolol in reducing intraocular pressure is most likely a decrease in aqueous humor production. Levobunolol reduces intraocular pressure with little or no effect on pupil size in contrast to the miosis which cholinergic agents are known to produce. |
| List of Excipients |
|---|
|
Poly(vinyl alcohol) |
Low density polyethylene (LDPE) blow-fill-seal unit dose container (0.9 ml volume) filled with 0.4 ml solution.
Unit dose containers are packaged into a foil covered pouch (2 strips of 5 containers per pouch).
Pouches are packaged into cartons such that each carton contains 30 or 60 unit dose containers.
Allergan Limited, Marlow International, The Parkway, Marlow, Buckinghamshire, SL7 1YL, United Kingdom
PL 00426/0072
20th April 1993 / 26th July 2003
| Drug | Countries | |
|---|---|---|
| BETAGAN | Brazil, France, Ireland, New Zealand, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
